Solvay

Feds Scrutinize Deals Delaying Generic Drugs

The Feds -- and consumers -- may finally have had it with 'pay-for-delay.' In these deals, generic drug companies that challenge a patent held by a name-brand pharmaceuticals agree to settle by delaying their entry into the market in return for a payment. But regulators are now calling for laws to end the practice.